{"filings":[{"id":95663,"accession_number":"0001193125-26-212064","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences Q1 net loss $3.0M; cash $14.1M; FDA agrees to adaptive Phase 2/3 study","event_type":"earnings","confidence":"high","bullets":["Net loss $3.0M ($2.71/share) vs $2.1M ($25.34/share) in Q1 2025; operating cash burn $3.2M.","Cash and equivalents $14.1M at March 31, 2026, up from $10.7M at Dec 31, 2025; cash runway through Q1 2027.","FDA agreed to a single adaptive Phase 2/3 study design for Gemini in acute kidney injury patients.","Received $6.7M net proceeds from January 2026 warrant inducement.","Presented positive additional data analysis from PRIME Study at AKI & CRRT 2026 conference."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108883,"accession_number":"0001193125-26-116012","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["3.03","5.07","9.01"],"status":"ready","headline":"REVB stockholders approve share issuance above Exchange Cap; Class J warrants expiry set to March 2031","event_type":"other_material","confidence":"high","bullets":["Stockholders approved issuance of shares exceeding 20% of outstanding (For 4,033,345, Against 104,162, Abstain 34,228).","Class J Common Stock Warrants expiration extended to March 18, 2031 (5 years from stockholder approval on March 18, 2026).","Special Meeting quorum was 4,171,735 shares (39.8% of 10,492,469 outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108882,"accession_number":"0001193125-26-076833","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences reports Q4 and FY2025 results; cash $10.7M, net loss $8.9M","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $10.7M as of Dec 31, 2025 vs $6.5M in 2024; net proceeds of $6.7M from warrant inducement in January 2026","Net loss for FY2025 was $8.9 million ($23.95 per share) vs $15.0 million ($1,052.16 per share) in FY2024","Announced positive results from PRIME clinical study in late-stage chronic kidney disease patients","Reached agreement with FDA on a single adaptive Phase 2/3 study for Gemini to treat acute kidney injury","Clinical data on Gemini for AKI and CKD to be presented at International Conference on Advances in Critical Care Nephrology (March 29-April 1, 2026)"],"consensus_eps_estimate":null,"consensus_eps_actual":-23.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108881,"accession_number":"0001193125-26-027742","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Revelation Biosciences raises ~$7.3M via warrant exercise; issues new warrants","event_type":"other_material","confidence":"high","bullets":["Two holders exercised 8,544,999 pre-split Class I warrants at $0.86/share, gross proceeds ~$7.3M.","Company issued 17,089,998 pre-split new Class J warrants at $0.86/share, exercisable only after stockholder approval.","Net proceeds to fund clinical development and working capital.","Third investor withdrew; filing corrects earlier press release that had included them.","Roth Capital Partners received 8% cash fee of gross proceeds as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108880,"accession_number":"0001193125-26-018332","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences reaches FDA agreement on approval pathway for Gemini AKI treatment","event_type":"regulatory","confidence":"high","bullets":["FDA agreed single Phase 2/3 adaptive study (~300 patients) can support NDA for Gemini in AKI.","Primary composite endpoint: death and/or need for dialysis; clinically relevant and objective.","Study design: randomized, double-blind, placebo-controlled; Part 1 dose finding, Part 2 Phase 3.","Company to engage CRO, advisors, and manufacture drug supply in 2026 before study start."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125342,"accession_number":"0001193125-25-306915","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["3.03","5.07","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences reports positive Phase 1b Gemini results; plans Phase 2/3 AKI study in 2026","event_type":"other_material","confidence":"high","bullets":["Phase 1b CKD study completed with positive results; Gemini rebalances inflammation at cellular level.","CEO expects FDA meeting later in 2025 to discuss clinical/regulatory pathways for acute kidney injury.","Company plans to start Phase 2/3 AKI study in 2026, building manufacturing and CRO infrastructure.","Stockholders approved share issuance related to warrants; warrant expiration fixed to Dec 3, 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125341,"accession_number":"0001193125-25-269696","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences Q3 net loss $1.9M, cash $12.7M; cash runway through Q3 2026","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2025 was $1.9M ($1.77 per share) vs $2.2M ($40.15) in Q3 2024.","Cash and equivalents $12.7M at Sept 30, 2025, up from $6.5M at Dec 31, 2024.","Received $9.6M gross proceeds from warrant inducement in September 2025.","Announced top-line results from PRIME clinical study; plans FDA meeting for Gemini registration path.","Net cash used in operations $6.3M for 9 months 2025 vs $14.6M in same period 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125340,"accession_number":"0001193125-25-256367","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Revelation Biosciences cancels Oct 29 special meeting due to voting technical issue; rescheduled to Dec 3","event_type":"other_material","confidence":"high","bullets":["Special Meeting of Stockholders canceled due to technical difficulty preventing all shares from being voted.","Meeting originally set for Oct 15, adjourned to Oct 29, now canceled.","New record date set as October 29, 2025.","New Special Meeting of Stockholders scheduled for December 3, 2025.","Company to issue new proxy materials to stockholders of record as of new record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125339,"accession_number":"0001193125-25-240400","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Revelation Biosciences adjourns Oct 15 special meeting to Oct 29 due to no quorum","event_type":"other","confidence":"high","bullets":["Special Meeting adjourned because insufficient shares were present to form a quorum.","Meeting reconvenes virtually on October 29, 2025 at 12:00 p.m. ET.","Record date remains September 11, 2025; stockholders who already voted need not act.","Company urges all stockholders to vote before the new meeting date.","Proxy materials and additional voting instructions available on SEC's website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142058,"accession_number":"0001193125-25-203750","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences raises $9.6M via immediate exercise of existing warrants","event_type":"other_material","confidence":"high","bullets":["$9.6M gross proceeds from exercise of 13,065,000 existing warrants at $2.20/share.","Issued 13,065,000 new Class I warrants at same $2.20 price, exercisable after stockholder approval for 5 years.","Existing warrants covered 4,355,000 shares; new warrants cover 13,065,000 shares (higher dilution).","Proceeds to fund clinical development and working capital.","Roth Capital Partners acted as financial advisor for 8% cash fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142057,"accession_number":"0001810560-25-000006","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Revelation Biosciences PRIME Phase 1b CKD study hits endpoints; Gemini reduces inflammation in high-background patients","event_type":"other_material","confidence":"high","bullets":["Gemini met primary safety endpoint; well-tolerated at target dose with only mild Grade I events.","In patients with high background inflammation (≈50%), Gemini significantly reduced IL-1β, TNF-α, IL-6, IL-10, IL-1RA vs placebo (p<0.01) through 7 days.","Gemini restored normal cellular response to LPS/HMGB1 stimuli in high-background PBMCs, reversing immunoparalysis (IL-1β p<0.0001).","Company scheduled End of Phase 1 meeting with FDA later in 2025 to discuss advancement.","40 patients enrolled across 5 dose cohorts in 3 US clinics; data webcast on Sept 10, 2025 at 8:30 AM ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142056,"accession_number":"0000950170-25-105485","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Revelation Biosciences Q2 net loss $2.4M; cash $5.2M; Gemini data due Q3","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2025 was $2.4M ($7.01 per share), improved from $8.4M ($246.27) in Q2 2024.","Cash and equivalents $5.2M at June 30, 2025, down from $6.5M at Dec 31, 2024; funds operations through Dec 2025.","Completed dosing in Phase 1b Gemini study in CKD; topline data expected later Q3 2025.","Raised $4M gross proceeds from public offering in May 2025.","Cash used in operations was $4.7M in Q2 2025 vs. $5.3M in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-13.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142055,"accession_number":"0000950170-25-094789","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences effects 1-for-3 reverse stock split; PRIME Phase 1b enrollment expected to complete July 2025","event_type":"other_material","confidence":"high","bullets":["1-for-3 reverse stock split effective July 7, 2025; post-split shares ~1,534,599.","Split intended to regain Nasdaq minimum bid price compliance; CUSIP changed to 76135L705.","PRIME Phase 1b study of Gemini in CKD patients: enrollment expected to complete July 2025; topline data anticipated shortly after."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160029,"accession_number":"0000950170-25-089972","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Revelation Bio shareholders approve reverse split up to 1:250; Nevada reincorporation fails despite 89% support","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized at ratio 1:2 to 1:250, board to set exact ratio within one year.","Issuance of common stock under May 2025 Class H Warrants above 20% exchange cap approved.","Reincorporation from Delaware to Nevada failed (89% of votes cast in favor, but not enough outstanding shares).","Lakhmir Chawla elected Class C director; advisory votes on exec compensation and frequency (3 years) passed.","Baker Tilly US ratified as auditor for FY2025; CEO presentation given but details not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160028,"accession_number":"0000950170-25-081604","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","3.03","8.01","9.01"],"status":"ready","headline":"Revelation Biosciences closes $4M public offering of common stock and warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4M from sale of 3,640,000 shares (or pre-funded warrants) plus warrants for up to 14,560,000 shares.","Warrants exercise price $1.10/share, exercisable after stockholder approval, expire 5 years from initial exercise date.","Net proceeds to fund Phase 1b study, clinical drug supply manufacture, preclinical work, and general corporate purposes.","Roth Capital Partners acted as sole placement agent; offering closed May 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160027,"accession_number":"0000950170-25-078340","cik":1810560,"company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVB","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Director George Tidmarsh resigns from Revelation Biosciences board to avoid conflict of interest","event_type":"leadership","confidence":"high","bullets":["George Tidmarsh, MD, PhD resigned from the Board on May 23, 2025, to avoid conflict with new US governmental agency work.","Board size reduced from 5 to 4; Lakhmir Chawla, MD reclassified as Class C Director.","Resignation was not due to any disagreement with the company's operations, policies, or practices.","Tidmarsh served as a Class C Director for 5 years; term was set to expire at the 2025 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}